GNTA

Genenta Science SpA Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website genenta.com
Employees(FY) -
ISIN US36870W1009

Performance

-2.29%

-14.55%

+12.57%

+42.42%

-5.05%

YTD

-13.76%

Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Advanced Technical Analysis

Technical Analysis of GNTA 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 30, Oscillators Score at 40, and a Technical Score of 35, indicating overall weakness in price momentum and suggesting caution for potential investors. The scores collectively highlight a lack of bullish signals, reinforcing a negative outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of GNTA

Stock Rank

Recent News & Updates

2024-10-22 19:00
Genenta's CEO to present at the U.S. Senate meeting on Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective(Globenewswire)
2024-10-01 18:30
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer(Globenewswire)
2024-09-29 17:12
Genenta Science S.p.A. (GNTA): Early Investment Opportunity in Innovative Biotech(Yahoo Finance)
2024-05-27 18:10
7 Penny Biotech Stocks to Triple Your Investment(Investorplace)
2024-05-05 18:25
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider(Globenewswire)
2024-02-07 16:00
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors(Globenewswire)
2023-09-05 19:00
Genenta to Present at Upcoming Scientific and Investor Conferences(Yahoo Finance)
2023-07-27 15:00
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments(Yahoo Finance)
2023-07-07 21:57
Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation(Yahoo Finance)
2023-06-28 19:00
The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma(Yahoo Finance)
2023-05-16 18:34
Insiders own 30% of Genenta Science S.p.A. (NASDAQ:GNTA) shares but individual investors control 59% of the company(Yahoo Finance)
2023-05-15 19:00
Genenta to Provide Update on Lead Product Temferon(Yahoo Finance)
2023-05-08 19:15
Sidoti's Micro-Cap Virtual May Conference(Yahoo Finance)
2023-05-02 03:30
Sidoti's Micro-Cap Virtual May Conference(Yahoo Finance)
2023-04-25 19:00
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing(Yahoo Finance)
2023-04-02 19:00
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications(Yahoo Finance)
2023-03-01 17:45
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme(Yahoo Finance)
2023-02-06 18:00
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement(Yahoo Finance)
2023-01-28 18:45
We Think Genenta Science (NASDAQ:GNTA) Can Easily Afford To Drive Business Growth(Yahoo Finance)
2022-12-07 16:16
Genenta Science S.p.A. (NASDAQ:GNTA) most popular amongst individual investors who own 60%, insiders hold 29%(Yahoo Finance)
2022-11-06 19:05
Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon Treatment in Glioblastoma Patients(Yahoo Finance)
2022-10-23 19:30
Genenta Provides First Half 2022 Business Update and Financial Results(Yahoo Finance)
2022-10-16 22:27
10 Best Italian Stocks To Buy Now(Yahoo Finance)
2022-10-04 20:05
Genenta to Present at Upcoming Scientific and Investor Conferences(Yahoo Finance)
2022-09-06 19:00
Genenta to Present at Upcoming Investor Conferences(Yahoo Finance)
2022-08-21 19:06
We're Not Very Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Rate(Yahoo Finance)
2022-07-24 18:00
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative(Yahoo Finance)
2022-05-26 21:40
What Kind Of Investors Own Most Of Genenta Science S.p.A. (NASDAQ:GNTA)?(Yahoo Finance)
2022-05-12 19:30
Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA(Yahoo Finance)
2022-05-08 19:30
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.